Rafi S. Ahmed - Vaccines

Author Information

Rafi Ahmed is a prominent researcher affiliated with the Emory Vaccine Center and Department of Microbiology and Immunology at Emory University School of Medicine, located in Atlanta, GA, USA. His work primarily focuses on vaccine research, immunology, and infectious diseases.

Research Contributions

Rafi Ahmed has made significant contributions to the field of immunology and vaccine research. His recent work includes studying the influence of pre-existing SARS-CoV-2 immunity on the humoral response to vaccination, exploring broad protection mechanisms against ebolaviruses, and examining antibody responses in patients with various conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and lung cancer after SARS-CoV-2 mRNA vaccination. His research also delves into the persistence of virus-specific antibodies and immune memory after SARS-CoV-2 infection and vaccination.

Aliases

Rafi Ahmed is also known by the following aliases: R Ahmed, R. Ahmed, Rafi Ahmed, and Rafi S. Ahmed.

Publication and Citation Metrics

Metric	Value
Citation Count	95,059
h-index	150
Paper Count	667

Publications:

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

DOI: 10.1016/j.xcrm.2022.100603

Year: 2022

Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses

DOI: 10.1016/j.cell.2022.02.023

Year: 2022

Persistence of Virus-Specific Antibody after Depletion of Memory B Cells

DOI: 10.1128/jvi.00026-22

Year: 2022

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.

DOI: 10.1200/JCO.22.00088

Year: 2022

In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles

DOI: 10.1126/sciadv.abm7950

Year: 2022

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.

DOI: 10.1200/JCO.21.02257

Year: 2022

Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.

DOI: 10.1101/2022.01.03.22268599

Year: 2022

Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant

DOI: 10.1101/2021.02.02.21250799

Year: 2021

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

DOI: 10.1101/2021.04.19.21255739

Year: 2021

Response to Whole-Lung Low-Dose Radiation Therapy (LD-RT) Predicts Freedom from Intubation in Patients Receiving Dexamethasone and/or Remdesevir for COVID-19-Related Acute Respiratory Distress Syndrome (ARDS)

DOI: 10.1101/2021.02.10.21251242

Year: 2021

What are Nanoparticles?

How Are Vaccine Manufacturers Responding?

What Challenges Exist in Vaccine Management?

How is GIS Used in Vaccine Surveillance?

How Do Public Health Campaigns Address Vaccine Hesitancy?

How Can You Manage Pain at the Injection Site?

Are Vaccines Safe for Children?

Why Mimic the Infection Instead of Using the Pathogen Itself?

What are Supplementary Immunization Activities (SIAs)?

What is the Immune System?

Partnered Content Networks

Relevant Topics